Psilocybin therapy gains traction amid new research for mental health conditions and legal developments in Colorado and New York shaping the future of psychedelic medicine.
Psilocybin, the active compound in psychedelic mushrooms, is increasingly viewed as a groundbreaking therapeutic tool in the treatment of mental health conditions. Recent clinical research, paired with evolving legislative developments in Colorado and New York, highlights the potential of psilocybin-assisted psychotherapy. While scientific evidence continues to build, public perception and legal frameworks are shifting to accommodate the promising role of psychedelics in modern medicine. Here’s what the latest data and policy changes tell us about the future of psilocybin therapy.
New research highlights long-term mental health benefits
Two major studies published in late 2024 and early 2025 underscore the growing interest in psilocybin’s potential to treat severe mental health conditions. The first study, conducted by researchers at NYU Langone Health, focused on cancer patients dealing with psychological distress, including anxiety, depression, and obsessive thoughts. Published in Nature Mental Health, the research found that psilocybin-assisted psychotherapy resulted in significant, lasting improvements. According to lead author Petros Petridis, MD, “Our findings suggest that the mental health benefits of psilocybin therapy for cancer patients may reach far beyond what we have previously understood.”
The trial involved 79 cancer patients who were split into two groups: one received a high dose of psilocybin, while the other was given either vitamin B3 or a microdose of psilocybin as a placebo. Psychotherapy sessions preceded and followed each dosing. After six or seven weeks, depending on the trial, the groups switched treatments, ensuring all participants experienced the therapeutic effects of psilocybin. Participants reported reduced anxiety, decreased anger, and fewer physical symptoms related to psychological distress. Notably, the benefits persisted for up to six months after the second dose.
Senior author Stephen Ross, MD, a clinical professor at NYU Grossman School of Medicine, emphasized the importance of safety in psilocybin use: “Their analysis adds to the mounting body of evidence that psilocybin can be safely administered under close medical supervision.” Importantly, no participants reported lasting paranoia or psychosis.
In a second study published in The American Journal of Psychiatry, researchers explored the use of psilocybin to treat alcohol use disorder. This trial examined personality changes in patients undergoing psilocybin-assisted psychotherapy. Over eight months, 83 participants received either psilocybin or an antihistamine placebo. Results showed that those treated with psilocybin experienced reduced impulsivity, depression, and emotional vulnerability. According to study lead author Broc Pagni, PhD, “Since impulsiveness has long been linked to both excessive drinking and relapse after treatment, the personality changes brought about by psilocybin-assisted psychotherapy may help those recovering from alcohol dependence remain resilient to internal and external stressors known to trigger relapse.”
Researchers also noted gender-based differences in outcomes: male participants were more likely to experience heightened positive emotions, while female participants showed increased openness to new experiences. The study authors aim to explore whether these personality changes are also evident in trials focused on opioid-use disorder.
Psychedelic legalization: a model for the future?
The research comes as Colorado became the second state in the United States to legalize psilocybin therapy, following Oregon’s lead. The decision, which went into effect on January 1, came after voters approved a 2022 ballot measure to permit therapeutic use of psilocybin. However, implementing the new law has not been without controversy.
In Colorado Springs, conservative leaders sought to restrict access to psychedelic treatment despite objections from veterans who advocate for its benefits in treating post-traumatic stress disorder (PTSD). Special forces veteran Lane Belone, who credits psilocybin therapy for helping him manage PTSD symptoms, urged local officials to reconsider proposed restrictions. “We have an opportunity to support veterans, and it’s a really easy one to say ‘Yes’ to,” said Belone during a recent city council meeting.
Despite such appeals, the Colorado Springs City Council voted to extend the prohibition on healing centers within one mile of schools, effectively limiting the number of available treatment centers. While state law prevents cities from outright banning psilocybin therapy, local governments can impose zoning and operational restrictions. Councilmember David Leinweber acknowledged the distinction between marijuana and psilocybin, stating, “Marijuana is literally killing our kids,” while expressing support for psilocybin therapy due to its potential to address serious mental health issues.
Unlike marijuana, psilocybin remains highly regulated. Only licensed facilitators can administer the substance in a therapeutic setting. Patients must undergo a comprehensive risk assessment, participate in preparatory and follow-up sessions, and remain under supervision during treatment. The psilocybin used in therapy is subject to rigorous testing, and businesses cultivating the mushrooms are closely monitored by state agencies.
Meanwhile, New York legislators are making strides toward legalizing psilocybin-assisted therapy. A bill prefiled for the 2025 session by Senator Nathalia Fernandez (D) and five cosponsors proposes a framework for psilocybin treatment, focusing on accessibility and safety. If passed, certified facilitators would be allowed to provide psilocybin therapy to patients with qualifying conditions, either in clinical settings or at home for those unable to travel.
A key component of the bill is the creation of a Psilocybin Assisted Therapy (PAT) grant program. With a proposed budget of $5 million, the program aims to subsidize treatment costs for veterans, first responders, and low-income individuals. This initiative seeks to ensure equitable access to psilocybin therapy, particularly for communities disproportionately affected by mental health challenges.
Senator Fernandez had previously introduced a similar bill, but it failed to advance out of committee. Minor technical revisions have been made in the latest version, which proponents hope will garner broader support. An attached memo highlights the urgency of addressing the mental health crisis: “As a State, it is our duty to use every tool at our disposal to alleviate that suffering for New Yorkers.”
Assemblymember Pat Burke (D), a sponsor of a related bill to establish a psilocybin therapy pilot program for 10,000 participants, underscored the need for immediate action. “We’re in a mental health crisis, and so we need every tool that’s available to us,” said Burke. Similarly, Assemblymember Linda Rosenthal (D) has advocated for broader psychedelic reform, introducing legislation to legalize certain psychedelics, including psilocybin and ibogaine, for adults over 21.
Despite promising research and legislative progress, significant hurdles remain. Critics, including some medical professionals, caution that the field of psychedelic medicine is still in its infancy. Jeffrey Lieberman, a professor of psychiatry at Columbia University, expressed concern about the rapid pace of legalization efforts. “I’m very positive about the potential value, but I’m very concerned that we’ve gotten too far ahead of our skis,” he said, noting that insufficient regulation could lead to patient exploitation and adverse outcomes.
Cost is another barrier to widespread adoption. In Oregon, where psilocybin therapy began in mid-2023, a single session can cost as much as $2,000. Although only a handful of emergency interventions have been reported among the more than 16,000 doses administered, critics argue that high costs may limit access to those who can afford out-of-pocket expenses.
Advocates counter that waiting for federal approval could prolong the suffering of those in need. Taylor West, executive director of the Healing Advocacy Fund, emphasized the urgency of expanding access: “This is a crisis that we are in, and this is a tool that we can add to our toolbox.”
Related on Ethos:
